April 2012
- LRG mourns the loss of a great friend, Jeroen Pit
- GDOL Update: Speakers announced
- LRG Research Team meets in Leuven, Belgium: leaves with renewed energy & commitment to finding the cure for GIST
- Meet our new Montana local rep: Dirk Niebaum
- Cellular origin of GIST from the “good” cells’ perspective
- Alianza GIST meets in Miami
- And they’re off! 1st ‘Harness a Cure’ is a success
- NJ GIST gathering serves up support & smoothies
- NoCal GISTers meet!
- New report finds most hospital errors go unreported
- Happy Cancerversary to Brenda Bannon!
- Thomas G. Overley, 1952-2012: Toledo lawyer played guitar, sang in group
- Durham lived life with passion and pride
- Did You Hear? Did You Know?
- Arizona GISTers meet!
- Spunky Texan fought GIST bravely
- Calendar
Archive
July 2009
Myelodysplastic syndromes developing after imatinib therapy for GIST
Abstract 10532, P. Spadaro, MD, Casa di Cura Villa Salus, Messina, Italy
In a prospective study of 49 GIST patients, the authors conclude that during imatinib therapy some patients with GIST develop chromosomal abnormalities and that, although rare, these findings highlight the need for monitoring GIST patients treated with imatinib.
A series of 49 patients were given bone marrow biopsies and blood tests before and after starting imatinib therapy in 2007 and 2008. 15 patients developed grade 3 or 4 low red cell or white cell counts while on imatinib. On microscopic analysis of bone marrow cells, eight patients (16%) showed some form of chromosomal abnormality. Of these, four were intermittent and not clinically significant; three were associated with a chronic low blood-count condition and one developed into Acute Myeloid Leukemia (AML). Although this study was not designed to answer the question, the authors speculate that imatinib may be the cause of the chromosomal abnormalities.
Abstract #: 10532
0 Comments